Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease

被引:3
|
作者
Tajima, Naoyuki
Nagashima, Satoru
Uematsu, Toshihiko
Torii, Hideki
Tajima, Masami
Hishida, Akira
Naganuma, Hideo
机构
[1] Sankyo Co Ltd, Clin Pharmacol & Biostat Dept, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[3] Shitoro Clin, Hamamatsu, Shizuoka 4328067, Japan
[4] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan
关键词
prediction; pharmacokinetics; hemodialysis; end-stage renal disease (ESRD); antibiotic;
D O I
10.1248/bpb.29.1454
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel and convenient method to predict the pharmacokinetics of several kinds of antibiotic agents in patients with end-stage renal disease (ESRD) was examined based on the in vitro extraction ratios and pharmacokinetic parameters in healthy volunteers. The dializability of 17 antibiotic agents in 4% human serum albumin solution were determined using a high-performance hemodialytic membrane for clinical use. We assumed that the off-hemodialysis clearance approximated the non-renal clearance, while the on-hemodialysis clearance was considered to be sum of the off-hemodialysis clearance and the hemodialytic clearance. The estimated on- and off-hemodialysis clearances were compared with the ones observed in ESRD patients. In order to confirm the method prospectively, an in vivo pharmacokinetic study was performed in dogs with mercury chloride-induced experimental renal failure. The in vitro extraction ratios of 9 beta-lactams were broadly ranged from 10.9 to 75.6% depending on their physicochemical properties. In contrast, those of the other antibiotics were consistent with their chemical classes: 60.5-63.2% for fluoroquinolone, 48.8-51.1% for aminoglycoside and 18.7-25.6% for glycopeptide. Both the estimated on- and off-hemodialysis clearances of the 17 antibiotics coincided well with the observed values in the literature, regardless of their physicochemical and pharmacokinetic properties. The validity and applicability of this method to three cefems, cefmetazole, cefotaxime and cefoperazone, was prospectively confirmed in the animal study. In conclusion, this new method enables the prediction of the on- and off-hemodialysis clearances of several kinds of antibiotics in ESRD patients from minimal information of their pharmacokinetics in healthy subjects and their in vitro dializability.
引用
收藏
页码:1454 / 1459
页数:6
相关论文
共 50 条
  • [31] PHARMACOKINETICS OF INTRAVENOUS VANCOMYCIN IN PATIENTS WITH END-STAGE RENAL-FAILURE
    TAN, CC
    LEE, HS
    TI, TY
    LEE, EJC
    THERAPEUTIC DRUG MONITORING, 1990, 12 (01) : 29 - 34
  • [32] The nature of impairments of memory in patients with end-stage renal disease (ESRD)
    Jones, Daniel J. W.
    Harris, John P.
    Vaux, Emma
    Hadid, Rebecca
    Kean, Rebecca
    Butler, Laurie T.
    PHYSIOLOGY & BEHAVIOR, 2015, 147 : 324 - 333
  • [33] Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis
    Teigen, Mette Maja B.
    Duffull, Stephen
    Dang, Lily
    Johnson, David W.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (11) : 1259 - 1267
  • [34] Management of pain in end-stage renal disease patients: Short review
    Raina, Rupesh
    Krishnappa, Vinod
    Gupta, Mona
    HEMODIALYSIS INTERNATIONAL, 2018, 22 (03) : 290 - 296
  • [35] Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment
    Caro, Luzelena
    Wenning, Larissa
    Feng, Hwa-Ping
    Guo, Zifang
    Du, Lihong
    Bhagunde, Pratik
    Fandozzi, Christine
    Panebianco, Deborah
    Marshall, William L.
    Butterton, Joan R.
    Iwamoto, Marian
    Yeh, Wendy W.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (05) : 665 - 675
  • [36] Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment
    Luzelena Caro
    Larissa Wenning
    Hwa-Ping Feng
    Zifang Guo
    Lihong Du
    Pratik Bhagunde
    Christine Fandozzi
    Deborah Panebianco
    William L. Marshall
    Joan R. Butterton
    Marian Iwamoto
    Wendy W. Yeh
    European Journal of Clinical Pharmacology, 2019, 75 : 665 - 675
  • [37] Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis
    Patel, Kashyap
    Rayner, Craig R.
    Giraudon, Mylene
    Kamal, Mohamed A.
    Morcos, Peter N.
    Robson, Richard
    Kirkpatrick, Carl M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (04) : 624 - 635
  • [38] The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
    Sica, DA
    Gehr, TWB
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, 3 (04) : 247 - 254
  • [39] Influence of ALDH2 Genetic Polymorphisms on Aciclovir Pharmacokinetics following Oral Administration of Valaciclovir in Japanese End-stage Renal Disease Patients
    Hara, Katsutoshi
    Suyama, Kazuaki
    Itoh, Hiroshi
    Nagashima, Satoru
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (05) : 306 - 312
  • [40] End-stage renal disease in leprosy
    Lomonte, C
    Chiarulli, G
    Cazzato, F
    Giammaria, B
    Marchio, G
    Losurdo, N
    Antonelli, M
    Casucci, F
    Basile, C
    JOURNAL OF NEPHROLOGY, 2004, 17 (02) : 302 - 305